


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula I:



FORMULA I

wherein substituents R1-R7 and X are defined as follows:

R1, R2, R3 and R4 each independently are selected from hydrogen, halogen (selected from F, Cl, Br or I), a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C₁₋₆alkyloxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkylamino, carboxyl, cyano, nitro, formyl, hydroxy, and CO-R, COO-R, CONH-R, and SO₂-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, CL, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

R5 is one of the following:

- (i) hydrogen, or
- (ii) a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br

or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

(iii) CO-R8 or COOR8 or CONHR8 or SO₂R8 wherein R8 may be

a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C₁₋₆alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, and amino, the latter nitrogen substituents optionally in the form of a pendant basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, CL, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

a heteroaryl group such as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C₁₋₆alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, and amino, the latter nitrogen substituents

optionally in the form of a pendant basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

R6 and R7 each independently are selected from :

i) hydrogen, a halogen (selected from F, Cl, Br or I), or

ii) an alkyl¹ group defined as a linear, branched or cycloalkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen (the latter optionally in the form of a pendant basic nitrogen functionality); as well as trifluoromethyl, carboxyl, cyano, nitro, formyl ; as well as CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R is a linear or branched alkyl group containing 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as a cycloalkyl or aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality, or

(iii) an aryl¹ group defined as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as

halogen (selected from I, F, Cl or Br);

alkyl¹ group;

a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality;

trifluoromethyl, O-alkyl¹ carboxyl, cyano, nitro, formyl, hydroxy, NH- alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;

NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹, aryl or heteroaryl, or

(iv) a heteroaryl¹ group defined as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as

halogen (selected from F, Cl, Br or I);

an alkyl¹ group;

a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality,

trifluoromethyl, O-alkyl¹ carboxyl, cyano, nitro, formyl, hydroxy, NH- (alkyl¹), alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;

NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹, or

(v) an O-aryl¹, or NH-aryl¹, or O-heteroaryl¹ group

(vi) trifluoromethyl, O-alkyl¹, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality, or

(vii) NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹, aryl or heteroaryl.

X is :

-NR⁹R¹⁰, wherein R⁹ and/or R¹⁰ are hydrogen or:


- i) an alkyl¹ group, CF₃ or
 - ii) an aryl¹, heteroaryl¹ or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality, or
 - iii) a CO-R, COO-R, CON-RR' or SO₂-R, where R and R' are a hydrogen, alkyl¹, aryl¹, or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality;
- or:

-CO-NR⁹R¹⁰, wherein R⁹ and/or R¹⁰ are hydrogen or:

- i) an alkyl¹ group, CF₃ or
- ii) an aryl¹, heteroaryl¹, or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality.


-alkyl¹.

2. (Original) A compound according to claim 1 of formula I-2 :



wherein R⁵ = H, Y and Z represents an hydrogen, an aryl¹ or a heteroaryl¹ group, optionally substituted by a pendant basic nitrogen functionality and wherein R¹, R², R³, R⁴, R⁶, and R⁷ have the meaning as defined in claim 1.


3. (Original) A compound according to claim 1 of formula II:



FORMULA II

Wherein Y is selected from O, S and Z corresponds to H, NRaRb, alkyl¹, aryl¹, O-alkyl¹, or O-aryl¹, or wherein Ra and Rb are independently chosen from H or alkyl¹ or aryl¹ or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R5, R6, and R7 have the meaning as defined in claim 1.


4. (Original) A compound according to claim 3 of formula II-1:



FORMULA II-1

Wherein R5 = H, Y = O or S and Ra, Rb are independently chosen from H or alkyl¹ or aryl¹ or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

5. (Original) A compound according to claim 4 of formula II-2:




FORMULA II-2

Wherein A is or heteroaryl¹ and

wherein R1, R2, R3, R4, R6, R7, aryl¹, heteroaryl¹ have the meaning described on pages as defined in claim 1.


6. (Original) A compound according to claim 4 of formula II-3 :



FORMULA II-3

Wherein R is independently alkyl¹, aryl¹, or heteroaryl¹ and wherein R1, R2, R3, R4, R5, R6, and R7 have the meaning described as defined in claim 1.


7. (Original) A compound according to claim 4 of formula II-4:



FORMULA II-4

Wherein R1, R2, R3, R4, R6, R7 and alkyl¹ have the meaning as defined in claim 1.


8. (Original) A compound according to claim 1 of formula I-3 :



FORMULA I-3

Wherein R5 = H, X is NHSO₂R group, R is independently alkyl¹, aryl¹, or heteroaryl¹ and wherein , alkyl¹, aryl¹, or heteroaryl¹, R1, R2, R3, R4, R6 and R7 have the meaning as defined in claim 1.


9. (Original) A compound according to claim 1 of formula III:



FORMULA III

Wherein Y is selected from NRaRb, NHNRaRb, alkyl¹, aryl¹, Ra wherein Ra and Rb are independently chosen from H or alkyl¹ or aryl¹ or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

10. (Original) A compound according to claim 1 of formula IV:



FORMULA IV

Wherein alkyl¹, R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

11. (Original) A compound as claimed in claim 1 selected from :

4- {[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoic acid methyl ester;

4-Methyl-M- (5-pyridin-3-yl-oxazol-2-yl)-N3- (5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine ;

4-Methyl-N1- (5-phenyl-oxazol-2-yl)-N3- (5-pyridin-4-yl-oxazol-2-yl)-benzene-1, 3-diamine;

4-Methyl-M- (5-phenyl- [1, 3,4] oxadiazol-2-yl)-N3- (5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine ;

N1-Benzooxazol-2-yl-4-methyl-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1, 3-diamine ;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

2-Cyano-N- [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

2-Ethoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

3-Methoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-propionamide ;

1- [4-Methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-p-tolyl-urea ;

1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1-(4-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1-(2-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl) -urea;

1-(4-Chloro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1- [4-Methyl-3- (5-phenyl-oxazol-2-ylamino)-phenyl]-3- (3-trifluoromethyl-phenyl)-
urea;

1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-
thiourea;

1- (4-Cyano-phenyl)-3- [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-
thiourea;

(2- {2-Methyl-5- [3- (4-trifluoromethyl-phenyl)-ureido]-phenylamino}-oxazol-5-yl)-
acetic acid ethyl ester;

1-Benzyl-3-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-thiourea ;

4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-
phenyl]-benzamide ;

3-Dimethylamino-N- [4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]- benzamide ;

3-Bromo-N- [4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide ;

N-[4-Methoxy-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-
benzamide;

4- (3-Dimethylamino-propylamino)-N [4-methyl-3- (5-pyridin-3-yl-oxazol-2-
ylamino)-phenyl]-3-trifluoromethyl-benzamide ;

N-[4-Fluoro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-
benzamide;

1H-indole-6-carboxylic acid [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-
amide;

3-Isopropoxy-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide ;

N-[4-Methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;

3, 5-Dimethoxy-N [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;

N-[3-(5-Pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide ;

N- [4-Methyl-3- (5-phenyl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide ;

3-Fluoro-4- (4-methyl-piperazin-1-ylmethyl)-N- [4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino) -phenyl] -benzamide ;

N-[4-Chloro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;

N- [4-Methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-terephthalamide ;

5-Methyl-isoxazole-4-carboxylic acid [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-amide ;

4-Cyano-N [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide ;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-isonicotinamide ;

N- [4-Methyl-3- (4-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;

[4-Methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;

(5-Isobutoxycarbonylamino-2-methyl-phenyl)- (5-pyridin-3-yl-oxazol-2-yl)-carbamic acid isobutyl ester;

[4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;

N-[4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-m-tolyl-acetamide ;

2-(4-Fluoro-phenyl)-N-[4-methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;

2-(2, 4-Difluoro-phenyl)-N-[4-methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-acetamide;

2-(3-Bromo-phenyl)-N-[4-methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-acetamide;

3-(4-Fluoro-phenyl)-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-propionamide;

2-(4-Fluoro-phenyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;

N-{3-[5-(4-Cyano-phenyl)-oxazol-2-ylamino]-4-methyl-phenyl}-2-(2, 4-difluoro-phenyl)-acetamide;

4-Methyl-pentanoic acid [4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-amide;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-2-piperazin-1-yl-acetamide;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-piperazin-1-yl-propionamide;

2-(2, 6-Dichloro-phenyl)-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-pyrrolidin-1-yl-propionamide;

N-[4-Methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-(4-trifluoromethyl-phenyl)-acetamide ;

2-(4-Methoxy-phenyl)-N- [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;

N- [4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-C-phenyl-methanesulfonamide ;

N-(4-Cyano-phenyl)-4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-benzamide ;

N- (3-Dimethylamino-phenyl)-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;

N-(2-Dimethylamino-ethyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;

N- (3-Fluoro-4-methyl-phenyl)-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;

N-(3-Chloro-phenyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide ;

N-Benzyl-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide ;

N-(4-Methoxy-benzyl)-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide ;

[4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-morpholin-4-yl-methanone ;

[4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-piperazin-1-yl-methanone ;

N-(4-Fluoro-phenyl)-2-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide

12. (Previously Presented) A compound according to claim 1, wherein R₆ is hydrogen and R₇ is pyridyl, which may additionally bear any combination, at any one ring position, of one or more substituents such as

- halogen (selected from F, Cl, Br or I) ;
- an alkyl¹ group;

- an aryl¹ group;
- trifluoromethyl, O-alkyl¹, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl¹, N (alkyl¹) (alkyl¹), and amino, the latter nitrogen substituents optionally in the of a basic nitrogen functionality; or
- NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl or group.

13. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1.

14. (Original) A pharmaceutical composition according to claim 13 further comprising a pharmaceutically acceptable carrier.

15. (Original) A pharmaceutical composition according to claim 14 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, and suspensions.

16. (Previously Presented) A cosmetic or pharmaceutical composition for topical administration comprising a compound according to claim 1.

17-22. (Canceled)

23. (New) A method for treatment of a neoplastic disease which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1,

wherein the neoplastic disease is selected from the group consisting of mastocytosis, canine mastocytoma, solid tumours, human gastrointestinal stromal tumor ("GIST"), small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, myeloma 414, colorectal carcinomas, gastric carcinomas, badder gastrointestinal stromal tumors, testicular cancers, glioblastomas, astrocytomas, bladder cancer and cancer in the airway tracts.

24. (New) A method for treatment of an allergic disease which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1,

wherein the allergic disease is selected from the group consisting of asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis and insect bite skin inflammation and blood sucking parasitic infestation.

25. (New) A method for treatment of an inflammatory disease which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1,

wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.

26. (New) A method for treatment of an autoimmune disease which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1,

wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, and proliferative glomerulonephritis.

27. (New) A method for treatment of graft-versus-host disease or graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung, and bone marrow which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1.